Drug interactions
Fondaparinux + Ticagrelor
Severity: Major
Fondaparinux and Ticagrelor: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Combining an antiplatelet P2Y12 inhibitor with a parenteral anticoagulant increases the risk of bleeding. The combination is often used deliberately in acute coronary syndromes, but bleeding events are more frequent than with either drug alone.
What this interaction means in plain words
Fondaparinux and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Fondaparinux belongs to Cardiovascular; Ticagrelor belongs to Cardiovascular.
Why it happens
Additive hemostatic impairment: ticagrelor blocks platelet P2Y12 receptors while fondaparinux inhibits factor Xa via antithrombin.
What to do
Use only when there is a clear indication, for the shortest necessary duration, and monitor for bleeding and hemoglobin changes. Adjust or stop fondaparinux if bleeding occurs, especially with renal impairment.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Fondaparinux and Ticagrelor, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Fondaparinux
- Defibrotide + Fondaparinux Contraindicated
- Fondaparinux + Ketorolac Contraindicated
- Abciximab + Fondaparinux Major
- Aceclofenac + Fondaparinux Major
- Acetylsalicylic acid + Fondaparinux Major
- Alteplase + Fondaparinux Major
Other interactions of Ticagrelor
- Itraconazole + Ticagrelor Contraindicated
- Ketoconazole + Ticagrelor Contraindicated
- Levoketoconazole + Ticagrelor Contraindicated
- Abciximab + Ticagrelor Major
- Abrocitinib + Ticagrelor Major
- Acalabrutinib + Ticagrelor Major
Frequently asked questions
Can I take Fondaparinux with Ticagrelor?
MediHelp rates the interaction as major. Fondaparinux and Ticagrelor can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Combining an antiplatelet P2Y12 inhibitor with a parenteral anticoagulant increases the risk of bleeding. The combination is often used deliberately in acute coronary syndromes, but bleeding events are more frequent than with either drug alone.
How serious is the interaction between Fondaparinux and Ticagrelor?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use only when there is a clear indication, for the shortest necessary duration, and monitor for bleeding and hemoglobin changes. Adjust or stop fondaparinux if bleeding occurs, especially with renal impairment.
What other medicines interact with Fondaparinux?
MediHelp also lists interactions of Fondaparinux with, for example, Defibrotide, Ketorolac, Abciximab. The full list is on the Fondaparinux page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
